Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ENASIDENIB vs ENCORAFENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

ENASIDENIB vs ENCORAFENIB: Safety Overview

Metric ENASIDENIB ENCORAFENIB
Total FAERS Reports 3,704 8,554
Deaths Reported 967 1,397
Death Rate 26.1% 16.3%
Hospitalizations 1,143 2,334
Average Patient Age 70.3 yrs 64.4 yrs
% Female Patients 43.6% 50.9%
FDA Approval Date Aug 1, 2017 Jun 27, 2018
Manufacturer Celgene Corporation Array BioPharma Inc.
Route ORAL ORAL
Marketing Status Prescription Discontinued